Back to today’s briefing

Story perspectives

Johnson & Johnson's Gene Therapy Trial Fails to Improve Vision

5/6/2025

43 10

Summary

Story summary

In a disappointing turn, the LUMEOS phase 3 trial by Johnson & Johnson found that the gene therapy bota-vec did not improve vision-guided mobility for patients suffering from X-linked retinitis pigmentosa (XLRP). Out of 95 participants, all faced adverse events, though some secondary endpoints hinted at potential benefits, warranting deeper analysis.

1 of 1

Story summary

In a disappointing turn, the LUMEOS phase 3 trial by Johnson & Johnson found that the gene therapy bota-vec did not improve vision-guided mobility for patients suffering from X-linked retinitis pigmentosa (XLRP). Out of 95 participants, all faced adverse events, though some secondary endpoints hinted at potential benefits, warranting deeper analysis.